Summit Therapeutics has a potential blockbuster successor to Keytruda in the shape of PD-1/VEGF bispecific ivonescimab, and has now expanded its key Phase III lung cancer study to maximize its opportunities.
Summit Doubles Down On Lung Cancer With Ivonescimab Trial Expansion
The changes expand the commercial potential of the PD-1/VEGF targeting immunotherapy's trial, but worries about delays and endpoint success have reigned in Summit's formerly skyrocketing share price.
More from Clinical Trials
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.